Philip Morris International: World Health Organization Report on Tobacco Fails People Who Currently Smoke
The following is a statement from Philip Morris International.
On July 26, the World Health Organization released a report on global tobacco use which urges governments to step up efforts to help smokers quit. There is no question that the best choice is never to start using cigarettes or nicotine-containing products or if someone has, they should quit altogether. By encouraging governments to double down on efforts to help men and women who smoke quit, the WHO takes an admirable stance. But the reality is that even with the best treatments available today, many people will not succeed. In any given year, about nine out of 10 men and women who are already smoking will continue to do so; in turn, their risk of smoking-related disease will continue to increase. We, as a society, cannot turn our backs on those people.
Surprisingly, this report, funded by Bloomberg Philanthropies, fails to acknowledge the robust science and innovation behind alternatives to smoking cigarettes. The WHO misses a critical scientific point: It is the burning of tobacco that produces the vast majority of the harmful chemicals that cause smoking-related diseases, not tobacco itself. Hundreds of millions of men and women who don’t quit stand to gain the most from less harmful alternatives to cigarettes. In fact, a global survey of 31,000 people in 31 countries found that 88 percent of respondents think smokers should have access to less harmful alternatives to cigarettes. https://www.pmi.com/media-center/news/public-supports-alternatives-to-cigarettes. PMI’s alternatives alone have already helped 8 million people abandon cigarettes entirely.
“The WHO is failing the 1 billion men and women around the world that continue to smoke by continuing to ignore the science behind better alternatives to cigarettes,” said Dr. Moira Gilchrist, Vice President of Strategic and Scientific Communications, Philip Morris International. “There is no question that scientifically substantiated smoke-free alternatives are better than cigarettes. The WHO is perfectly situated to encourage independent research and provide science-based recommendations to smokers. Instead they seem to be closing down dialogue on promising alternatives to continued smoking, choosing instead to focus solely on pharmaceutical industry products.”
In 1997, the UN Focal Point on Tobacco or Health recommended that “in order to assist smokers who are so heavily dependent that they cannot possibly stop smoking, every effort should be made to reduce the toxicity of existing tobacco products.” The same report also recommends that “the WHO is requested to consider the above recommendations in future policy-development activities, including the drafting of a framework convention on tobacco control.”
PMI heeded the call for reduced toxicity products and for more than 20 years has been working on developing and scientifically assessing less harmful alternatives to cigarettes that do not create smoke, because they do not combust. PMI’s scientific assessment program is inspired by the well-recognized practices of the pharmaceutical industry and in line with the draft guidance of the U.S. FDA for Modified Risk Tobacco Product (MRTP) Applications. Our scientific studies resulted in more than 340 references in peer-reviewed articles in scientific journals and book chapters. All our clinical studies are registered on the public website www.ClinicalTrials.gov.
We encourage rigorous assessment of our scientific research, which is made transparently available for just that purpose. To date, there have been 73 independent studies and scientific reviews from universities and government research institutes in countries like Germany, Japan and the United Kingdom. In general, the conclusions from these studies and reviews are in line with PMI’s own data.
Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, outlines in his own vision statement that “under my leadership an enhanced and independent WHO will take a science-led and innovation-based approach that is results-oriented and responsive, maximizes inclusive partnerships, and ensures collective priority setting with all stakeholders.” https://www.who.int/dg/vision
One has to ask, why does the WHO not apply these same principles to tobacco control?
“We remain committed to having an open and transparent dialogue based on science,” said Dr. Gilchrist. “We cannot change the past, but we can change the future for the 1 billion people around the world who continue to smoke.”
Our smoke-free strategy complements efforts by the WHO to tackle smoking. Our aspiration is that, by 2025, at least 40 million people who would otherwise have smoked cigarettes will have switched to our smoke-free products (approximately 8 million people to date globally), reducing the number of smokers of PMI cigarette brands by a total 55 million by 2025. Our aspiration is to reduce smoking almost four times faster than the target set by WHO.
“We are shifting our business toward science-based better alternatives. We look forward to working with decision-makers in governments around the world and organizations such as the WHO to accelerate this transformation,” said Dr. Gilchrist. “Despite the WHO report, we remain steadfast in our commitment to unsmoke the world.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2019, PMI estimates that approximately 8.0 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 48 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com.
Philip Morris International Media Office
T: +41 (0)58 242 4500
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Declares Dividend for Fourth Quarter 201912.12.2019 00:15:00 EET | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent and nutrition announced that its Board of Directors has declared a regular quarterly cash dividend of $0.75 per share of its common stock, payable on January 7, 2020 to shareholders of record as of December 27, 2019. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005907/en/ Contact information Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com
Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy12.12.2019 00:05:00 EET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA submission is based on data from the Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. “There remains a significant need
PTW International Announces Orange Rock Studios, Their Product and Game Development Arm11.12.2019 20:00:00 EET | Press release
Pole to Win International, Ltd. (PTW), the industry-leading video games and tech services outsourcer, today announced the launch of its product and game development arm, Orange Rock Studios. Orange Rock Studios will enhance the service offering of PTW, a gaming industry stalwart with an established and diverse dossier of top-tier clients across multiple verticals. “The time to be disruptive is now,” said Deborah Kirkham, CEO of PTW. “At Orange Rock, we foster future technologies to anchor projects with ingenuity and discipline for generation Y and Z. Together with our clients, we envision and engineer digital experiences.” “Orange Rock is the engine that will build PTW’s future by enabling us to bring each of our existing service lines - Quality Assurance, Customer Support, Audio Production, Localization, and Translation - to the forefront of their fields through cutting edge in-house tool development. We will deliver the creative products that accelerate our industry’s progress toward
Fastly Shares the Most Notable Internet Infrastructure Milestones of 2019, and What 2020 Might Bring for the Expansion of Platform-Independent Computing11.12.2019 19:30:00 EET | Press release
Fastly, Inc. (NYSE: FSLY), provider of a global edge cloud platform, today released its “Behind the Screens” retrospective detailing 2019’s notable milestones in internet infrastructure, from the increased adoption of modernized protocols, to the growth in reach and capacity of global high-speed internet, and more. Fastly’s CTO and co-founder, Tyler McMullen, anticipates that these advancements, combined with the rise of WebAssembly and the extension of code portability across platforms and devices, set the programming world up for achieving broader value from serverless computing. The State of Internet Infrastructure in 2019 This year saw a groundswell of grassroots protocol improvements, sweeping shifts toward encryption due to increased focus on data privacy, and a preview into WebAssembly’s possibilities at the edge, as well as: New satellites that took to the sky and submarine cables that were installed to grow capacity around the globe. Congestion control reimagined through BBR,
Invicro Supports the Alzheimer’s Disease Neuroimaging Initiative11.12.2019 18:37:00 EET | Press release
Invicro LLC, a Konica Minolta Company, today announced funding support for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and two of their distinguished scientists within the Alzheimer’s biomarkers space, Drs. Roger Gunn and Kenneth Marek, will join the ADNI-Private Partner Scientific Board (PPSB). Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development. ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI’s mission strives to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease’s progression with biomarkers, as well as support advances in AD intervention, prevention, and treatment. “Invicro is delighted to support ADNI which plays a central role in the development of biomarkers that enable advances in AD interven
Sevan Elevate Brings Safety and Sustainability to New Heights11.12.2019 17:00:00 EET | Press release
Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in data analytics, surveys, design, program management and construction services, is excited to announce the launch of Sevan Elevate, a program that will reinforce and continuously improve Safety and Sustainability across the company to deliver excellence to people and clients. Safety and Sustainability have been a strategic imperative since 2011 when Sevan was founded by a handful of entrepreneurs, including President and CEO Jim Evans. “Sevan’s tenets are Safety and Sustainability—both of which are woven through every element of the company. It is imperative that all our people—including team members, clients and business partners—return home safely to their loved ones at the end of the day,” Evans said. “With Sevan Elevate, the company is more committed than ever to raise awareness and compliance of Safety and Sustainability throughout the multi-site construction world. We’re not going to change the world overnight, but we ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom